Aribiolab acquires KRW 2.45 billion Aribio Holdings convertible bond

By Public Technologies
  • Aribiolab set to buy KRW 2.4 billion of Aribio Holdings’ 9th convertible bond, paying KRW 2.448 billion.
  • Transaction slated for Sept. 29, 2026; framed as a strategic move to generate synergy in its bio business.
  • Bond carries a 2% coupon, 8% yield-to-maturity; matures June 5, 2029.
  • Conversion price set at KRW 3,412 per share; up to 1,465,416 shares upon conversion.
  • Includes a put option starting June 5, 2027, with step-up early redemption prices through March 5, 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aribiolab Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260929900449), on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.